Scienza e Tecnologia
Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU
Game Changing sessions are reserved for Phase III trials or other developments that the EAU's Scientific Congress Office believes will have a large impact on daily practice.
New data presented:
Professor Dr. Peter Mulders commented, "I'm delighted to be at EAU, the leading urological event in Europe , sharing further detailed results from Telix's Phase III ZIRCON study with the medical community. New data reinforces the clinical potential of this investigational agent, even in small renal masses which are most prevalent and present the highest diagnostic challenge, with remarkable consistency across readers. On behalf of Telix, I'd like to thank all the European sites and patients for their participation in this ground-breaking study."
Telix is in the process of establishing expanded access studies and supporting named patient programs for TLX250-CDx in the United States and Europe .
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United States , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
TLX250-CDx has not received a marketing authorisation in any jurisdiction. Telix's lead product, gallium-68 ( Ga) gozetotide (also known as Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA), and by the Australian Therapeutic Goods Administration (TGA), and by Health Canada.
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com
Legal Notices
Top line data released to ASX on 7 November 2022.
ASX disclosure 20 December 2021 .
ASX disclosure 2 November 2021 .
ASX disclosure 14 October 2022 .
Logo - https://mma.prnewswire.com/media/1920208/3935222/TeliMain_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/telixs-zircon-phase-iii-kidney-cancer-imaging-study-presented-in-game-changing-session-at-eau-301770710.html